

## CURRICULUM VITAE

### 이준엽

가톨릭의과대학 서울성모병원 내분비내과



#### [학력]

2006-2012	가톨릭의과대학 학사
2015-2017	가톨릭의과대학 내과학 석사
2017-2021	한국과학기술원 의과학대학원 박사

#### [경력]

2012-2013	가톨릭중앙의료원 수련의
2013-2017	가톨릭중앙의료원 전공의
2017-2021	한국과학기술원 의과학대학원
2021-2023	서울성모병원 내분비내과 전임의
2023-2024	서울성모병원 내분비내과 임상진료조교수
2024-	서울성모병원 내분비내과 조교수

#### [관심분야]

췌도부전, 디지털 헬스케어, 비만

#### [논문]

1. Prediction of Cardiovascular Complication in Patients with Newly Diagnosed Type 2 Diabetes Using an XGBoost/GRU-ODE-Bayes-Based Machine-Learning Algorithm. *Endocrinol Metab (Seoul)* 2023; doi: 10.3803/EnM.2023.1739
2. Multiparity increases the risk of diabetes by impairing the proliferative capacity of pancreatic  $\beta$  cells. *Experimental & Molecular Medicine* 2023;55:2269-2280.
3. Risk of Cause-Specific Mortality across Glucose Spectrum in Elderly People: A Nationwide Population-Based Cohort Study. *Endocrinol Metab (Seoul)* 2023; doi: 10.3803/EnM.2023.1765
4. Opening the Precision Diabetes Care through Digital Healthcare. *Diabetes Metab J* 2023; doi: 10.4093/dmj.2022.0386
5. PRMT1 Is Required for the Maintenance of Mature  $\beta$ -Cell Identity. *Diabetes*. 2020;69(3):355-68.

## KDA - Role of continuous glucose monitoring in diabetic patients at high cardiovascular risk

Joonyub Lee

Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul St. Mary's Hospital,  
College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

Glycemic homeostasis is an important factor in the development and prognosis of cardiovascular diseases. Patients with diabetes are at an increased risk of cardiovascular disease, which can often lead to fatal outcomes. Fluctuations in blood glucose levels, including hyperglycemia, hypoglycemia, and glycemic variability, are associated with adverse cardiovascular outcomes. Continuous Glucose Monitoring (CGM) systems, as wearable devices, provide real-time, high-quality glycemic data, offering a novel approach to managing diabetes. The adoption of CGM among diabetic patients has rapidly increased recently, driven by its potential

to significantly reduce hyperglycemia, hypoglycemic episodes, and glycemic variability. Despite the growing evidence supporting CGM's benefits in glycemic management, its impact on diabetic patients with a high risk of cardiovascular events remains to be fully elucidated. This talk aims to explore the latest evidence on the effectiveness of CGM in managing patients with diabetes who are at high cardiovascular risk. By examining recent clinical studies and outcomes, we will discuss whether CGM can offer benefits in reducing cardiovascular risk among this high-risk patient population.